Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in California: - Kaiser Permanente-Anaheim — Anaheim, California
- Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
- PCR Oncology — Arroyo Grande, California
- Sutter Auburn Faith Hospital — Auburn, California
- Sutter Cancer Centers Radiation Oncology Services-Auburn — Auburn, California
Phase 3 Recruiting Academic/Other
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …
Sponsor: NRG Oncology
NCT ID: NCT06748222
Sites in California: - Kaiser Permanente-Anaheim — Anaheim, California
- Kaiser Permanente-Deer Valley Medical Center — Antioch, California
- AIS Cancer Center at San Joaquin Community Hospital — Bakersfield, California
- Kaiser Permanente-Baldwin Park — Baldwin Park, California
- Kaiser Permanente-Bellflower — Bellflower, California
Phase 3 Recruiting Industry
This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06393374
Sites in California: - MemorialCare Orange Coast Medical Center ( Site 9501) — Fountain Valley, California
- Scripps Cancer Center ( Site 0052) — La Jolla, California
- Cancer and Blood Specialty Clinic ( Site 0008) — Los Alamitos, California
- Kaiser Permanente - Oakland ( Site 0079) — Oakland, California
- Profound Research LLC ( Site 0105) — Oceanside, California
Phase 3 Recruiting Industry
This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metasta…
Sponsor: BriaCell Therapeutics Corporation
NCT ID: NCT06072612
Sites in California: - Los Angeles cancer Network_Anaheim — Anaheim, California
- Comprehensive Blood and Cancer Center — Bakersfield, California
- Cedars-Sinai Cancer Beverly Hills — Beverly Hills, California
- Los Angeles Cancer Network_Corona — Corona, California
- Los Angeles cancer Network_Fountain Vallley — Fountain Valley, California
Phase 3 Recruiting Industry
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizuma…
Sponsor: AstraZeneca
NCT ID: NCT06103864
Sites in California: - Research Site — Duarte, California
- Research Site — Fountain Valley, California
- Research Site — Glendale, California
- Research Site — Sacramento, California
- Research Site — Santa Rosa, California
Phase 3 Recruiting Industry
The purpose of this study is to investigate the efficacy and safety of BGB-43395 in combination with letrozole compared with investigator's choice of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) in combination with letrozole in patients…
Sponsor: BeOne Medicines
NCT ID: NCT07492641
Sites in California: - Helios Clinical Research the Oncology Institute Fountain Valley — Fountain Valley, California
- California Research Institute — Los Angeles, California
- Ventura County Hematology Oncology Specialists — Oxnard, California
Phase 3 Recruiting Industry
The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+,…
Sponsor: AstraZeneca
NCT ID: NCT06380751
Sites in California: - Research Site — Fountain Valley, California
- Research Site — Glendale, California
- Research Site — Los Angeles, California
- Research Site — Newport Beach, California
Phase 3 Recruiting Industry
This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutati…
Sponsor: Relay Therapeutics, Inc.
NCT ID: NCT06982521
Sites in California: - Beverly Hills Cancer Center — Beverly Hills, California
- City of Hope National Medical Center — Duarte, California
- Cedars-Sinai Medical Center — Los Angeles, California
- Stanford Women's Cancer Center — Palo Alto, California
- University of California, Davis Comprehensive Cancer Center — Sacramento, California
Phase 3 Recruiting Industry
The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metasta…
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06435429
Sites in California: - The Oncology Institute Of Hope And Innovation — Cerritos, California
- Los Angeles Hematology Oncology Medical Group Glendale — Glendale, California
- USC-Norris Comprehensive Cancer Center - Investigational Drug Service IDS — Los Angeles, California
- UCSF at Mission Bay MB — San Francisco, California
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-pa…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06926868
Sites in California: - Helios Clinical Research — Cerritos, California
- Local Institution - 0307 — Cerritos, California
- Local Institution - 0308 — Cerritos, California
- Local Institution - 0309 — Cerritos, California
- Local Institution - 0311 — Long Beach, California
Phase 3 Recruiting Industry
This is a Phase III, multicenter, randomized, open-label, global study designed to evaluate the efficacy and safety of inavolisib plus fulvestrant compared with alpelisib plus fulvestrant in patients with hormone receptor (HR)-positive, hu…
Sponsor: Hoffmann-La Roche
NCT ID: NCT05646862
Sites in California: - Marin Cancer Care Inc — Greenbrae, California
- Cancer Blood and Specialty Clinic — Los Alamitos, California
- Los Angeles Cancer Network — Los Angeles, California
- University of California, Irvine Medical Center — Orange, California
- UC Davis Comprehensive Cancer Center — Sacramento, California
Phase 3 Recruiting Network
The purpose of this research study is to learn more about the effects of using proton radiation therapy delivered over a shorter course of treatment (3 weeks) compared with a longer, standard course of treatment (5 weeks) for women with br…
Sponsor: Proton Collaborative Group
NCT ID: NCT05856773
Sites in California: - California Protons Cancer Therapy Center — San Diego, California
Phase 3 Recruiting Industry
The purpose of this study is to understand treatment adherence and patient-reported outcomes of switching to giredestrant due to prior aromatase inhibitor (AI) intolerance. Giredestrant will be administered as adjuvant endocrine therapy fo…
Sponsor: Genentech, Inc.
NCT ID: NCT07541079
Sites in California: - Orange Coast Medical Center — Fountain Valley, California
Phase 3 Recruiting Academic/Other
Latrogenic infertility as a result of cancer treatment has a profound effect on long-term quality of life in survivors of reproductive-age cancers. Oocyte cryopreservation prior to cancer treatment has been associated with improved quality…
Sponsor: University of California, San Francisco
NCT ID: NCT03011684
Sites in California: - University of California at San Francisco — San Francisco, California
Phase 2 Recruiting Academic/Other
This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of …
Sponsor: Dana-Farber Cancer Institute
NCT ID: NCT04893109
Sites in California: - UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California
Phase 2 Recruiting Academic/Other
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators o…
Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT01042379
Sites in California: - University of California - Davis, Comprehensive Cancer Center — Davis, California
- City of Hope — Duarte, California
- University of California San Diego — La Jolla, California
- University of Southern California — Los Angeles, California
- HOAG Memorial Hospital Presbyterian — Newport Beach, California
Phase 2 Recruiting Industry
PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) …
Sponsor: Puma Biotechnology, Inc.
NCT ID: NCT06369285
Sites in California: - Beverly Hills Cancer Center — Beverly Hills, California
- MemorialCare Orange Coast Medical Center — Fountain Valley, California
- City of Hope at Orange County Lennar Foundation Cancer Center — Irvine, California
- LA Cancer Network — Los Angeles, California
- UCLA Department of Medicine - Hematology/Oncology — Los Angeles, California
Phase 2 Recruiting Industry
This study will include two groups of patients: Cohort 1 and Cohort 2. Cohort 1: will help researchers learn how a medicine called imlunestrant (LY3484356) affects a specific type of breast cancer. Some patients will take both imlunestrant…
Sponsor: Eli Lilly and Company
NCT ID: NCT07287098
Sites in California: - City of Hope — Duarte, California
- City of Hope Orange County Lennar Foundation Cancer Center — Irvine, California
- USC/Norris Comprehensive Cancer Center — Los Angeles, California
- UCLA Hematology/Oncology - Parkside — Santa Monica, California
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in California: - University of California Irvine Chao Family Comprehensive Cancer Center — Irvine, California
- University of San Diego Moores Cancer Center — La Jolla, California
- UCLA Jonsson Comprehensive Cancer Center — Los Angeles, California
- USC Norris Comprehensive Cancer Center — Los Angeles, California
Phase 2 Recruiting NIH
This phase II trial studies how well nab-paclitaxel, durvalumab, and tremelimumab with or without personalized synthetic long peptide vaccine (neoantigen vaccine) works in treating patients with triple negative breast cancer that has sprea…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03606967
Sites in California: - UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
- University of California Davis Comprehensive Cancer Center — Sacramento, California
Phase 2 Recruiting Industry
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary ce…
Sponsor: Fore Biotherapeutics
NCT ID: NCT05503797
Sites in California: - Precision NextGen Oncology & Research Center — Beverly Hills, California
- UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California
- University of California Los Angeles Rheumatology — Westwood, Los Angeles, California
Phase 2 Recruiting Industry
The Substudy Protocol ASPEN-09-03 is a Phase 2, single-arm, multicenter study evaluating the efficacy, safety, and tolerability of evorpacept in combination with trastuzumab and chemotherapy in participants with HER2-positive metastatic br…
Sponsor: ALX Oncology Inc.
NCT ID: NCT07007559
Sites in California: - City of Hope — Duarte, California
- UC San Diego Moores Cancer Center — La Jolla, California
- UC Irvine Health - Chao Family Comprehensive Cancer Center — Orange, California
Phase 1, Phase 2 Recruiting Industry
This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with breast cancer. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatmen…
Sponsor: Hoffmann-La Roche
NCT ID: NCT04802759
Sites in California: - City of Hope — Duarte, California
- City of Hope - Orange County Lennar Foundation Cancer Center — Irvine, California
- University of California, San Francisco (UCSF) — San Francisco, California
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center — Santa Monica, California
- Stanford Cancer Institute (SCI) — Stanford, California
Phase 2 Recruiting Academic/Other
The purpose of this study is to test the safety and effectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan, or datopotamab deruxtecan followed by trastuzumab deruxtecan) to lea…
Sponsor: Ana C Garrido-Castro, MD
NCT ID: NCT06533826
Sites in California: - University of San Francisco — San Francisco, California
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a fi…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT04895709
Sites in California: - Community Cancer Institute — Clovis, California
- USC/Norris Comprehensive Cancer Center — Los Angeles, California
- Hoag Memorial Hospital Presbyterian — Newport Beach, California